Cargando…
Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
INTRODUCTION: We compared the economic impacts of linezolid and vancomycin for the treatment of hospitalized patients with methicillin-resistant Staphylococcus aureus (MRSA)–confirmed nosocomial pneumonia. METHODS: We used a 4-week decision tree model incorporating published data and expert opinion...
Autores principales: | Patel, Dipen A, Shorr, Andrew F, Chastre, Jean, Niederman, Michael, Simor, Andrew, Stephens, Jennifer M, Charbonneau, Claudie, Gao, Xin, Nathwani, Dilip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220084/ https://www.ncbi.nlm.nih.gov/pubmed/25053453 http://dx.doi.org/10.1186/cc13996 |
Ejemplares similares
-
An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany
por: Patel, Dipen A, et al.
Publicado: (2014) -
Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy
por: Pletz, Mathias W, et al.
Publicado: (2010) -
Predictors of Clinical Success in the Treatment of Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Nosocomial Pneumonia (NP)
por: Shorr, Andrew F., et al.
Publicado: (2015) -
Pneumonia Caused by Community-Acquired Methicillin-Resistant Staphylococcus aureus: Vancomycin or Linezolid?
por: Tian, Ye, et al.
Publicado: (2018) -
Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People’s Republic of China
por: Lesher, Beth, et al.
Publicado: (2016)